[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352361-105":59,"doc-detail-352361-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-repurposing-dapagliflozin-via-polymeric-nanogels-for-colorectal-cancer-therapy","A repurposing Dapagliflozin via polymeric nanogels for colorectal cancer therapy","","Dapagliflozin (DAPA), an SGLT2 inhibitor approved for type 2 diabetes, is explored for repurposing in colorectal cancer to overcome limited solubility and rapid systemic clearance. An oral gravity-induced nano hydrogel mass system (DAPA-PVA-SA-NPs) using sodium alginate and polyvinyl alcohol nanoparticles improves solubility 1.8-fold and achieves 88.37% encapsulation with sustained gastrointestinal release. In vitro results show enhanced cytotoxicity and reduced oncogenic and inflammatory markers (KRAS, IL-6, TGF-β, TNF-α). Rat pharmacokinetics indicate delayed Tmax and an extended half-life with modest AUC improvement, supporting further evaluation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-repurposing-dapagliflozin-via-polymeric-nanogels-for-colorectal-cancer-therapy/352361/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-repurposing-dapagliflozin-via-polymeric-nanogels-for-colorectal-cancer-therapy/352361.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is Dapagliflozin being repurposed for colorectal cancer therapy?","Question",{"text":112,"@type":113},"The text highlights emerging oncology potential due to DAPA’s anti-inflammatory and antiproliferative properties, along with evidence of modulation of oxidative stress and inflammatory pathways.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What delivery system was developed to improve DAPA’s therapeutic utility?",{"text":117,"@type":113},"An oral gravity-induced nano hydrogel mass system encapsulating DAPA using sodium alginate and polyvinyl alcohol nanoparticles (DAPA-PVA-SA-NPs) was developed to enhance solubility and enable controlled release.",{"name":119,"@type":110,"acceptedAnswer":120},"What effects did the formulation show in vitro and in vivo?",{"text":121,"@type":113},"In vitro, the formulation improved cytotoxicity against HCT-116 colorectal cancer cells and downregulated oncogenic and inflammatory markers. In vivo in rats, it produced delayed Tmax and extended half-life, indicating prolonged systemic exposure with a modest AUC increase.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352361,1790510673,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nA repurposing Dapagliflozin via polymeric nanogels for colorectal cancer therapy  \nSamaa Abdullah1,6,7, Samar Thiab1,7, AbeerA. Altamimi2, AlaaA. Al-Masud3, Sarah Fahmi Faludah3 & Ahmed Saud Abdulhameed4,5  \nDapagliflozin (DAPA), a selective SGLT2 inhibitor approved for type 2 diabetes, shows emerging potential for repurposing in oncology due to its anti-inflammatory and antiproliferative properties. However, its poor solubility and rapid systemic clearance limit its therapeutic utility in cancer treatment. Here, we report the development of an oral novel gravity-induced nano hydrogel mass system encapsulating DAPA using sodium alginate (SA) and polyvinyl alcohol (PVA) nanoparticles (DAPA-PVA-SA-NPs). The formulation exhibited enhanced solubility (1.8-fold increase), high encapsulation efficiency (88.37%), and sustained release in simulated gastrointestinal conditions. In vitro studies demonstrated improved cytotoxicity against HCT-116 colorectal cancer cells and significant downregulation of oncogenic and inflammatory markers (KRAS, IL-6, TGF-β, TNF-α) . In vivo pharmacokinetic evaluation in rats showed delayed Tmax, extended half-life, and a 7% increase inAUC, indicating prolonged systemic exposure with modest AUC improvement. This delivery platform improves oral exposure in rats, shows in vitro activity in HCT-116 cells and supporting further exploratory evaluation for repurposing DAPA in colorectal cancer, pending confirmation in additional models.  \nKeywords Dapagliflozin, Polymeric nanogels, Drug repurposing, Colorectal cancer, Oral drug delivery system, In vivo absorption  \nColorectal cancer (CRC) remains a major global health burden, ranking among the leading causes of cancerrelated mortality worldwide. The aggressive nature of the disease, characterized by rapid progression and high recurrence, underscores the urgent need for novel therapeutic strategies or the repurposing of existing drugs to enhance treatment efficacy and improve patient outcomes1. Among emerging candidates for drug repositioning is Dapagliflozin (DAPA), a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor primarily used in the management of type 2 diabetes mellitus. By reducing glucose reabsorption in the renal proximal tubules, DAPA not only lowers blood glucose levels but also demonstrates pharmacological versatility that may be extended to oncology2,3. In recent years, the repurposing of SGLT2 inhibitors such asDAPA has emerged as a promising avenue in oncology, particularly due to their effects on glucose metabolism, oxidative stress, and inflammation pathways involved in tumour progression4,5. However, a key limitation in clinical translation lies in the inadequate sitespecific delivery and systemic bioavailability of DAPA when administered orally. This study aims to bridge this translational gap by employing a pH-responsive sediment-forming polymeric nanogel system that potentially prolongs gastric residence time and enables a controlled release profile favourable for colonic exposure. Unlike existing DAPA-loaded bilosomes, solid lipid nanoparticles (SLNs), or self-nanoemulsifying drug delivery systems (SNEDDS), which have demonstrated systemic absorption improvements6,7, our formulation uniquely targets the distal gastrointestinal tract via a sedimentation-mediated gel matrix. This distinction is of therapeutic importance given that CRC progression is heavily influenced by localized bioavailability and sustained drug exposure within the colonic region.  \n1Faculty of Pharmacy, Applied Science Private University, Amman 11937, Jordan. 2Natural and Health Sciences Research Centre, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, 11671 Riyadh, Saudi Arabia.  \n3Tissue Banking Section, Research department, Health Science Research Center, Princess Nourah Bint Abdulrahman University, 84428 Riyadh, Saudi Arabia. 4Department of Pharmaceutical Chemistry,","cbCaim1MAq649Mxt","https://ap.wps.com/l/cbCaim1MAq649Mxt","pdf",3352545,"English","# Dapagliflozin repurposing for colorectal cancer\n## Rationale and limitations of oral delivery\n## Development of the gravity-induced nano hydrogel system\n## Formulation performance and release in gastrointestinal conditions\n## Biological evaluation: in vitro cytotoxicity and marker downregulation\n## Biological evaluation: in vivo pharmacokinetics in rats\n## Molecular background of colorectal cancer and therapeutic targets","[{\"question\":\"Why is Dapagliflozin being repurposed for colorectal cancer therapy?\",\"answer\":\"The text highlights emerging oncology potential due to DAPA’s anti-inflammatory and antiproliferative properties, along with evidence of modulation of oxidative stress and inflammatory pathways.\"},{\"question\":\"What delivery system was developed to improve DAPA’s therapeutic utility?\",\"answer\":\"An oral gravity-induced nano hydrogel mass system encapsulating DAPA using sodium alginate and polyvinyl alcohol nanoparticles (DAPA-PVA-SA-NPs) was developed to enhance solubility and enable controlled release.\"},{\"question\":\"What effects did the formulation show in vitro and in vivo?\",\"answer\":\"In vitro, the formulation improved cytotoxicity against HCT-116 colorectal cancer cells and downregulated oncogenic and inflammatory markers. In vivo in rats, it produced delayed Tmax and extended half-life, indicating prolonged systemic exposure with a modest AUC increase.\"}]","A repurposing Dapagliflozin via polymeric nanogels for colorectal cancer therapy | PDF",1790099200,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6af204ac9b325a5e80aeb3d537b2c3ce.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34ba2c2cc8cf3e3cf15fe62df6f66fc2.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77fb370a6c58768ca005a933000825ce.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29631b0d77181ad796bf721fcedf8d06.webp",980,1287]